Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on May 24, 2010. The filing discloses the appointment of a new senior executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Mark O. Thornton, M.D., M.P.H., Ph.D. as Senior Vice President, Development and Chief Medical Officer, effective May 24, 2010. Dr. Thornton joins from Genvec, Inc., where he served as Senior Vice-President, Product Development.
Compensation and Employment Terms
- Base Salary: $315,000 annually.
- Performance Bonus: Target of 40% of base salary, payable in cash and/or restricted stock based on specified goals.
- Equity Grants:
- Stock options to purchase 200,000 shares at the closing price on the start date.
- 25,000 shares of restricted stock.
- Eligibility for additional performance-based stock awards.
- Severance: Entitled to a lump sum payment equal to 12 months of salary if terminated without cause or if he terminates for good reason.
- Restrictions: Includes a 12-month non-competition clause following termination.
Investor Verification Checklist
- Verify the closing stock price on May 24, 2010, to determine the exercise price of the 200,000 stock options granted.
- Review the attached Employment Agreement (Exhibit 10.1) for specific performance goals tied to the bonus structure.
- Confirm the impact of the new executive's compensation on the company's overall cash burn rate, given the company's pre-revenue status typical of biopharmaceutical firms.
- Check subsequent filings for updates on Dr. Thornton's tenure and the achievement of performance milestones.